Half-Year 2022 Financial and Clinical Trials Update
Changes to the development pipeline
HY 2022 update
2 NMES:
New to phase I
New to phase II
1 NME:
4 Als:
RG6237 latent myostatin + Evrysdi - SMA
RG6351 NME - retinal disease
RG6526 camonsertib - solid tumors
1 Al:
RG6264 Phesgo OBI - HER2+ BC
1 NME:
Removed from phase I
RG6338 NME - metabolic diseases
2 Als:
RG7440 ipatasertib + rucaparib - mCRPC,
solid tumors
RG7440 ipatasertib - prostate cancer,
pretreated
Status as of July 21, 2022
New to phase III
RG1594 Ocrevus SC - PPMS & RMS
RG6171 giredestrant + Phesgo - 1L ER+/HER2+
BC
RG1450 gantenerumab - early Alzheimer's
RG7828 Lunsumio (mosunetuzumab) + Polivy -
2L+ SCT ineligible DLBCL
Removed from phase II
Removed from phase III
1 NME:
RG6173 anti-tryptase - asthma
1 Al:
RG6171 giredestrant - 2/3L ER+/HER2- MBC
New to registration
Approvals
Roche
1 NME (EU):
RG7828 Lunsumio (mosunetuzumab) - 3L FL
1 AI (US):
RG7916 Evrysdi SMA presymptomatic pediatric
<2mo
2 Als (EU):
RG7596 Polivy - 1L DLBCL
RG7446 Tecentriq - NSCLC adj
73View entire presentation